Chemed (CHE) is back on investor screens after recent share price moves, with the stock closing at US$439.13 and showing mixed return patterns over the past month and past 3 months.

That recent move comes after a steady 9.57% 90 day share price return, even as the 1 year total shareholder return is down 19.73%. This suggests shorter term momentum has picked up while longer term holders are still under water.

If Chemed’s shift in momentum has caught your eye, it can be useful to compare it with other opportunities and see how many 39 healthcare AI stocks.

With Chemed trading at US$439.13 and sitting close to analyst targets yet showing an estimated 36% intrinsic discount, the key question is simple: is the stock undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 2% Undervalued

Chemed’s most followed valuation narrative pegs fair value at $446.50, slightly above the last close at $439.13. This frames the current discount as modest but visible.

The ramp-up of new Certificate of Need (CON) locations in underserved Florida counties (e.g., Pinellas and Marion) is expected to materially expand VITAS's service footprint, aligning with the continued aging U.S. population and the shift toward home-based care, both key drivers of higher patient volumes and long-term top-line revenue growth.

Want to see what sits behind that growth push, the revenue curve, the margin rebuild, and the future earnings multiple that ties it all together? The full narrative breaks down how patient volumes, profitability and share count assumptions connect to that $446.50 fair value.

Result: Fair Value of $446.50 (UNDERVALUED)

However, this hinges on VITAS managing Medicare reimbursement caps and on Roto-Rooter avoiding prolonged weak residential demand and higher costs that could pressure margins and earnings.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly mixed and both risks and rewards in play, now is a good time to look through the data yourself and pressure test the narrative against your own expectations, starting with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Chemed has sharpened your focus on valuation and momentum, do not stop here. Broaden your opportunity set with targeted stock ideas built from data driven screens.

• Hunt for mispriced quality by checking out 47 high quality undervalued stocks that pair strong fundamentals with compelling valuations.
• Strengthen income potential by reviewing 10 dividend fortresses designed for investors who care about consistency and yield.
• Prioritize financial resilience by scanning the solid balance sheet and fundamentals stocks screener (46 results) and focusing on companies with robust balance sheets and solid underlying businesses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.